TY - JOUR
T1 - Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent
AU - Lin, Weili
AU - Mukherjee, Pratik
AU - An, Hongyu
AU - Yu, Yingjing
AU - Wang, Yi
AU - Vo, Katy
AU - Lee, Benjamin
AU - Kido, Daniel
AU - Haacke, E. M.
PY - 1999/8
Y1 - 1999/8
N2 - Recently, a new imaging method was proposed by Reichenbach et al (Radiology 1997;204:272-277) to image small cerebral venous vessels specifically. This method, referred to as high-resolution blood oxygen level- dependent venography (HRBV), relies on the susceptibility difference between the veins and the brain parenchyma. The resulting phase difference between the vessels and the brain parenchyma leads to signal losses over and above the usual T2* effect. At 1.5 T, a rather long TE (roughly 40 msec) is required for this cancellation to become significant, leading to enhanced susceptibility artifacts and a long data acquisition time. In this study, we examine the utility of incorporating a clinically available T1 reducing contrast agent, Omniscan (Sanofi Winthrop Pharmaceuticals, NY, NY), with the HRBV imaging approach to reduce susceptibility artifacts and imaging time while maintaining the visibility of cerebral veins. Using a double-dose injection of Omniscan, we were able to reduce TE from 40 to 25 msec. This led to a decrease in TR from 57 to 42 msec, allowing a 26% reduction in data acquisition time while maintaining the visibility of cerebral venous vessels and reducing susceptibility artifacts.
AB - Recently, a new imaging method was proposed by Reichenbach et al (Radiology 1997;204:272-277) to image small cerebral venous vessels specifically. This method, referred to as high-resolution blood oxygen level- dependent venography (HRBV), relies on the susceptibility difference between the veins and the brain parenchyma. The resulting phase difference between the vessels and the brain parenchyma leads to signal losses over and above the usual T2* effect. At 1.5 T, a rather long TE (roughly 40 msec) is required for this cancellation to become significant, leading to enhanced susceptibility artifacts and a long data acquisition time. In this study, we examine the utility of incorporating a clinically available T1 reducing contrast agent, Omniscan (Sanofi Winthrop Pharmaceuticals, NY, NY), with the HRBV imaging approach to reduce susceptibility artifacts and imaging time while maintaining the visibility of cerebral veins. Using a double-dose injection of Omniscan, we were able to reduce TE from 40 to 25 msec. This led to a decrease in TR from 57 to 42 msec, allowing a 26% reduction in data acquisition time while maintaining the visibility of cerebral venous vessels and reducing susceptibility artifacts.
KW - BOLD
KW - Contrast agent
KW - Venogram
UR - http://www.scopus.com/inward/record.url?scp=0032773630&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1522-2586(199908)10:2<118::AID-JMRI2>3.0.CO;2-V
DO - 10.1002/(SICI)1522-2586(199908)10:2<118::AID-JMRI2>3.0.CO;2-V
M3 - Article
C2 - 10441013
AN - SCOPUS:0032773630
VL - 10
SP - 118
EP - 123
JO - Journal of Magnetic Resonance Imaging
JF - Journal of Magnetic Resonance Imaging
SN - 1053-1807
IS - 2
ER -